There is provided a pharmaceutical agent, food, or beverage for treating or preventing a disease or condition that can be ameliorated by inhibiting serotonin reuptake, comprising a clinically-effective amount of (1S,3S)-2-methyl-1,2,3,4-tetrahydro-²-carboline-3-carboxylic acid.